Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Korean J Hematol. 2012 Sep;47(3):178-185. English. Original Article. https://doi.org/10.5045/kjh.2012.47.3.178
Kim SJ , Jang JE , Cheong JW , Eom JI , Jeung HK , Kim Y , Hwang DY , Min YH .
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. minbrmmnd@yuhs.ac
Medical Research Center, Yonsei University College of Medicine, Seoul, Korea.
Abstract

BACKGROUND: The overexpression of Aurora A kinase (AurA) has been reported in various malignancies, including acute myeloid leukemia (AML). However, the expression of AurA and the effects of AurA inhibition in cancer stem cells are not yet fully understood. We investigated the expression and inhibition of AurA in AML stem cells (CD34+/CD38-). METHODS: Expression of AurA was investigated in cell lines (NB4 and KG1) that express high levels of CD34 and low levels of CD38. Primary AML cells were harvested from 8 patients. The expression of AurA and cell death induced by inhibition of AurA were analyzed in CD34+/CD38- cells. RESULTS: AurA was shown to be overexpressed in both primary AML cells and leukemia stem cells (LSCs) compared to normal hematopoietic stem cells. Inhibition of AurA plus cytarabine treatment in LSCs resulted in increased cytotoxicity compared to cytarabine treatment alone. Additional stimulation with granulocyte-colony stimulating factor (G-CSF) increased the cell death caused by AurA inhibition plus cytarabine treatment. CONCLUSION: To our knowledge, this is the first report describing increased expression of AurA in LSCs. Our results suggest that selective AurA inhibition may be used to reduce LSCs, and this reduction may be enhanced by stimulation with G-CSF. Further exploration of relationship between nuclear factor kappa-B and AurA inhibition and the potential of AurA inhibition for use in leukemia treatment is needed.

Copyright © 2019. Korean Association of Medical Journal Editors.